MetaCap

CareDx (CDNA) vs Veracyte (VCYT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CareDx (CDNA) has outperformed Veracyte (VCYT) over the past year, gaining 307.5% versus a loss of 42.9%. Over five years, CDNA leads with a +65.2% price change compared with -39.5% for VCYT. CareDx is the larger company by market cap ($3.68 billion vs $2.03 billion), about 1.8 times the size, while Veracyte is growing revenue faster (+16.0% vs +13.8%).

On valuation, Veracyte trades at a lower forward P/E (16.2x vs 44.7x for CareDx). Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus -5.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CDNA+307.45%VCYT-42.90%
+438%+185%-68%
Nov 21, 20251 yearNov 20, 2026
CDNA+62.75%VCYT-49.03%
+113%+7%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CDNA versus VCYT key metrics
MetricCDNAVCYT
Share price$70.00$25.13
Market cap$3.68B$2.03B
1-day change-2.67%+0.36%
YTD return+271.55%-40.31%
1-year return+307.45%-42.90%
5-year return+65.21%-39.53%
P/E ratio (TTM)29.5416.32
Forward P/E44.7516.15
EPS (TTM)$2.37$1.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$379.81M$517.14M
Revenue growth (YoY)+13.79%+16.01%
Net income (latest FY)$-21.35M$66.35M
Gross margin—70.10%
Operating margin-8.10%11.17%
Net margin-5.62%12.83%
52-week high$90.87$60.91
52-week low$15.56$21.91
Distance from 52-week high-22.97%-58.74%
Analyst consensusbuybuy
Avg. price target upside+34.90%+77.48%
Average volume1.30M1.89M
Shares outstanding52.54M80.70M
Employees761755
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CDNA has outperformed VCYT by 350.3 percentage points over the past year.
  • CareDx trades at a higher earnings multiple (29.5x vs 16.3x trailing P/E).
  • Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -5.6 cents for CareDx.

About CareDx

CDNA stock →

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.

Health Care · Medical Specialities · 761 employees

About Veracyte

VCYT stock →

Veracyte, Inc. operates as a diagnostics company in the United States and internationally.

Health Care · Medical Specialities · 755 employees

CDNA vs VCYT FAQ

Which is bigger, CareDx or Veracyte?

CareDx (CDNA) is larger, with a market capitalization of $3.68B compared with $2.03B for Veracyte (VCYT).

Which stock has performed better over the past year, CDNA or VCYT?

CDNA returned +307.45% over the past 12 months, compared with -42.90% for VCYT (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, CDNA or VCYT?

VCYT has the lower trailing P/E at 16.3, versus 29.5 for CDNA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are CareDx and Veracyte in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons